182 related articles for article (PubMed ID: 38685030)
21. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
[TBL] [Abstract][Full Text] [Related]
22. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.
Ky B; Putt M; Sawaya H; French B; Januzzi JL; Sebag IA; Plana JC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
J Am Coll Cardiol; 2014 Mar; 63(8):809-16. PubMed ID: 24291281
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
24. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
Bergamini C; Dolci G; Rossi A; Torelli F; Ghiselli L; Trevisani L; Vinco G; Truong S; La Russa F; Golia G; Molino A; Benfari G; Ribichini FL
Clin Cardiol; 2018 Mar; 41(3):349-353. PubMed ID: 29569424
[TBL] [Abstract][Full Text] [Related]
25. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells.
Dallons M; Alpan E; Schepkens C; Tagliatti V; Colet JM
Cells; 2020 Sep; 9(10):. PubMed ID: 32992522
[TBL] [Abstract][Full Text] [Related]
26. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
[TBL] [Abstract][Full Text] [Related]
27. The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.
Kirkham AA; Eves ND; Shave RE; Bland KA; Bovard J; Gelmon KA; Virani SA; McKenzie DC; Stöhr EJ; Waburton DER; Campbell KL
Breast Cancer Res Treat; 2018 Feb; 167(3):719-729. PubMed ID: 29110150
[TBL] [Abstract][Full Text] [Related]
28. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
Eppenberger-Castori S; Klingbiel D; Ruhstaller T; Dietrich D; Rufle DA; Rothgiesser K; Pagani O; Thürlimann B
BMC Cancer; 2020 Feb; 20(1):114. PubMed ID: 32046665
[TBL] [Abstract][Full Text] [Related]
29. Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients.
Marinko T; Stojanov Konda JT; Dolžan V; Goričar K
Dis Markers; 2020; 2020():6645588. PubMed ID: 33425072
[TBL] [Abstract][Full Text] [Related]
30. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
Burstein HJ; Harris LN; Gelman R; Lester SC; Nunes RA; Kaelin CM; Parker LM; Ellisen LW; Kuter I; Gadd MA; Christian RL; Kennedy PR; Borges VF; Bunnell CA; Younger J; Smith BL; Winer EP
J Clin Oncol; 2003 Jan; 21(1):46-53. PubMed ID: 12506169
[TBL] [Abstract][Full Text] [Related]
31. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity.
Anjos M; Fontes-Oliveira M; Costa VM; Santos M; Ferreira R
Life Sci; 2021 Sep; 280():119760. PubMed ID: 34166713
[TBL] [Abstract][Full Text] [Related]
32. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial.
Rüger AM; Schneeweiss A; Seiler S; Tesch H; van Mackelenbergh M; Marmé F; Lübbe K; Sinn B; Karn T; Stickeler E; Müller V; Schem C; Denkert C; Fasching PA; Nekljudova V; Garfias-Macedo T; Hasenfuß G; Haverkamp W; Loibl S; von Haehling S
J Am Heart Assoc; 2020 Dec; 9(23):e018143. PubMed ID: 33191846
[TBL] [Abstract][Full Text] [Related]
33. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
[TBL] [Abstract][Full Text] [Related]
34. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
[TBL] [Abstract][Full Text] [Related]
35. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM; Ewer MS; Viale G; Delaloge S; Ferrero JM; Verrill M; Colomer R; Vieira C; Werner TL; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C;
Ann Oncol; 2018 Mar; 29(3):646-653. PubMed ID: 29253081
[TBL] [Abstract][Full Text] [Related]
36. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
37. Cardiac Magnetic Resonance Imaging and Blood Biomarkers for Evaluation of Radiation-Induced Cardiotoxicity in Patients With Breast Cancer: Results of a Phase 2 Clinical Trial.
Speers C; Murthy VL; Walker EM; Glide-Hurst CK; Marsh R; Tang M; Morris EL; Schipper MJ; Weinberg RL; Gits HC; Hayman J; Feng M; Balter J; Moran J; Jagsi R; Pierce LJ
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):417-425. PubMed ID: 34509552
[TBL] [Abstract][Full Text] [Related]
38. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
Todorova VK; Makhoul I; Siegel ER; Wei J; Stone A; Carter W; Beggs ML; Owen A; Klimberg VS
PLoS One; 2016; 11(8):e0160224. PubMed ID: 27490685
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.
Uriarte-Pinto M; Escolano-Pueyo Á; Gimeno-Ballester V; Pascual-Martínez O; Abad-Sazatornil MR; Agustín-Ferrández MJ
Int J Clin Pharm; 2016 Apr; 38(2):446-53. PubMed ID: 26951122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
